Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 1
2002 1
2010 2
2011 1
2012 47
2013 5
2014 2
2015 3
2016 8
2017 6
2018 6
2019 13
2020 6
2021 14
2022 5
2023 20
2024 10
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Similar articles for PMID: 36795904

101 results

Results by year

Filters applied: . Clear all
Page 1
Teplizumab.
[No authors listed] [No authors listed] 2023 Jan 15. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. 2023 Jan 15. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. PMID: 36795904 Free Books & Documents. Review.
An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes.
Herold KC, Bundy BN, Long SA, Bluestone JA, DiMeglio LA, Dufort MJ, Gitelman SE, Gottlieb PA, Krischer JP, Linsley PS, Marks JB, Moore W, Moran A, Rodriguez H, Russell WE, Schatz D, Skyler JS, Tsalikian E, Wherrett DK, Ziegler AG, Greenbaum CJ; Type 1 Diabetes TrialNet Study Group. Herold KC, et al. N Engl J Med. 2019 Aug 15;381(7):603-613. doi: 10.1056/NEJMoa1902226. Epub 2019 Jun 9. N Engl J Med. 2019. PMID: 31180194 Free PMC article. Clinical Trial.
Teplizumab: First Approval.
Keam SJ. Keam SJ. Drugs. 2023 Apr;83(5):439-445. doi: 10.1007/s40265-023-01847-y. Drugs. 2023. PMID: 36877454 Review.
Teplizumab for treatment of type 1 diabetes mellitus.
Skelley JW, Elmore LK, Kyle JA. Skelley JW, et al. Ann Pharmacother. 2012 Oct;46(10):1405-12. doi: 10.1345/aph.1R065. Epub 2012 Sep 11. Ann Pharmacother. 2012. PMID: 22968521 Review.
Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trial.
Herold KC, Gitelman SE, Willi SM, Gottlieb PA, Waldron-Lynch F, Devine L, Sherr J, Rosenthal SM, Adi S, Jalaludin MY, Michels AW, Dziura J, Bluestone JA. Herold KC, et al. Diabetologia. 2013 Feb;56(2):391-400. doi: 10.1007/s00125-012-2753-4. Epub 2012 Oct 21. Diabetologia. 2013. PMID: 23086558 Free PMC article. Clinical Trial.
Teplizumab in Type 1 Diabetes Mellitus: An Updated Review.
Thakkar S, Chopra A, Nagendra L, Kalra S, Bhattacharya S. Thakkar S, et al. touchREV Endocrinol. 2023 Nov;19(2):22-30. doi: 10.17925/EE.2023.19.2.7. Epub 2023 Oct 6. touchREV Endocrinol. 2023. PMID: 38187075 Free PMC article. Review.
Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial.
Sherry N, Hagopian W, Ludvigsson J, Jain SM, Wahlen J, Ferry RJ Jr, Bode B, Aronoff S, Holland C, Carlin D, King KL, Wilder RL, Pillemer S, Bonvini E, Johnson S, Stein KE, Koenig S, Herold KC, Daifotis AG; Protégé Trial Investigators. Sherry N, et al. Lancet. 2011 Aug 6;378(9790):487-97. doi: 10.1016/S0140-6736(11)60931-8. Epub 2011 Jun 28. Lancet. 2011. PMID: 21719095 Free PMC article. Clinical Trial.
101 results